Breast cancer breakthrough for immunotherapy and Tecentriq

22 October 2018

For the first time, an immuno-oncology therapy has been shown to be effective against breast cancer, new data highlighted at the annual ESMO congress have shown.

At the Presidential Symposium on Saturday, Swiss cancer giant Roche (ROG: SIX) shared interim results from the Phase III IMpassion130 study of Tecentriq (atezolizumab) plus chemotherapy in the first-line treatment of certain people with triple-negative breast cancer.

The combo reduced the risk of disease worsening or death, with progression-free survival (PFS) of 7.2 months against 5.5 months in the control group.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK